DexCom, Inc. reported past first-quarter 2026 results with revenue of US$1,191.9 million, net income of US$199.5 million, and diluted EPS of US$0.51, while reaffirming full-year revenue guidance of ...

Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results , with sales up 15% year on year to $1.19 billion. The ...

DexCom, Inc. DXCM reported first-quarter 2026 adjusted earnings per share (EPS) of 56 cents, which beat the Zacks Consensus ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions ...

DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...

Pre-earnings options volume in DexCom (DXCM) is 2.4x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 6.7%, or $5.59, after results are released.

DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...

DexCom (NASDAQ: DXCM) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the ...

Predictions of a sales-growth slowdown sent DexCom stock tumbling this summer. Management predicted third-quarter sales would rise by just 1% to 3% year over year. Two of DexCom's top competitors ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...